|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8070 EUR | +25.51% |
|
+24.78% | -49.05% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 75.66x | 7.17x | -0.99x | 5.3x | 22.45x | 29.48x | 2.64% | 317B | ||
| 24.65x | 2.08x | -12.68x | 3.35x | 11.83x | 19.88x | 1.61% | 72.79B | ||
| 12.53x | 13.16x | 0.08x | 6.36x | 9.69x | 10.63x | - | 9.91B | ||
| 15.88x | 1.37x | 0.77x | 1.99x | 6.76x | 8.16x | 2.85% | 8.16B | ||
| 21.7x | 5.73x | 2x | 6.23x | 17.18x | 17.95x | -.--% | 4.51B | ||
| 36.88x | 2.41x | -1.7x | 2.35x | 27.49x | 42.15x | 0.75% | 3.94B | ||
| 31.87x | - | 0.2x | 6.06x | 17.32x | 28.05x | - | 3.71B | ||
| -146.59x | - | 2.77x | - | - | - | -.--% | 2.73B | ||
| 63.19x | - | -0.12x | - | - | - | - | 1.26B | ||
| 14.22x | 0.82x | -0.83x | 1.05x | 7.64x | 26.1x | 4.35% | 1.03B | ||
| -68.45x | 1.66x | 1.03x | - | - | - | - | 923M | ||
| 39.95x | 6.26x | -1.04x | 13.1x | 27.51x | 32.37x | - | 903M | ||
| Average | 10.12x | 4.52x | -0.88x | 5.09x | 16.43x | 23.86x | 1.74% | 35.57B | |
| Weighted average by Cap. | 61.05x | 6.23x | -2.86x | 4.92x | 19.93x | 26.95x | 2.41% |
- Stock Market
- Stocks
- AB Stock
- A8D Stock
- Sector AB Science
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
















